We are excited to announce that our ready-to-use liquid treatment created with PEARLᵀᴹ Technology, for frown lines and crow’s feet has been approved in Switzerland. #AdvancingDermatology #SkinScienceByGalderma

Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds. galderma.com/news/galderma-… $GALD

We’re excited to be attending the AMWC World Congress next week! We are looking forward to showcasing the latest developments in our unparalleled Injectable Aesthetics portfolio. Read more: galderma.com/news/amwc-2025… #AdvancingDermatology #SkinScienceByGalderma

Celebrating Galderma’s first year as a public company! On March 22, 2024, we listed on the SIX Swiss Exchange with one of the largest healthcare #IPOs ever. In year 2, we look forward to continuing to deliver on our purpose of #AdvancingDermatology for every skin story. $GALD

As we mark the first anniversary of Galderma's 2.3 billion CHF initial public offering (IPO), we’re proud to be shortlisted for PRWeek UK's Corporate Affairs Awards 2025 in the “Best Handling of an IPO” category. #PRWeekAwards #IPO #pr #CorporateCommunications

Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets galderma.com/news/galderma-…

Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology® galderma.com/news/alastin-r… #AdvancingDermatology

Watch #BeautyxMedicine featuring Dr. Weinstein and our CEO, F. Ørnskov, MD, MPH discuss the importance of patient education, balancing treatments with bespoke regimens, and following a ‘master plan’ to maintain skin health at every stage of life. youtu.be/-xV83yu31c0?fe…

Galderma’s Q1 2025 results were ahead of expectations, with 1.129 billion USD in net sales, up 8.3% year-on-year in constant currency. Learn more about our innovation progress in our press release: galderma.com/news/galderma-… #AdvancingDermatology #Q1results $GALD

We invite investors to attend our Galderma Q1 2025 earnings update today at 3:30pm CEST to learn more about our year-to-date performance: investors.galderma.com #AdvancingDermatology #Q1results $GALD

Watch the new episode of #BeautyxMedicine. CEO, Flemming Ørnskov, speaks with Dr. Jean Carruthers, known as the ‘godmother of cosmetic dermatology. Full episode: youtu.be/jl76Fj7tjiQ

Galderma news! Our treatment for moderate-to-severe #AtopicDermatitis and #PrurigoNodularis is now approved by Australia’s Therapeutic Goods Administration – marking its approval in all four selected countries within the Access Consortium framework. #ForInvestors

Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering galderma.com/news/shares-bu… #ShareRepurchase #InvestorRelations #Dermatology #CapitalAllocation

We are excited to share that new data on the long-term effects of our #AtopicDermatitis treatment will be presented at Revolutionizing AD 2025. Read more: bit.ly/4jDkxWX

We are excited to share that new data on the long-term effects of our prurigo nodularis treatment will be presented at the XIV International Congress of Dermatology (ICD). Read more: galderma.com/news/icd-2025-… #ForInvestors #ICD2025

We’re heading to #ICD2025 for the first time! Don’t miss Galderma’s symposium: “DITCHING THE ITCH.” where we will explore breakthroughs in #AtopicDermatitis & #PrurigoNodularis. Join us for our late breaker session with lead author, Dr. Sonja Ständer. #SkinSciencebyGalderma

We are pleased to announce two new clinical trials in #SystemicSclerosis and Chronic Pruritus of Unknown Origin (#CPUO). Find out more about the trials here: galderma.com/news/galderma-… #AdvancingDermatology #SkinScienceByGalderma #ForInvestors

We are pleased to announce new nine-month data showing how Galderma’s injectables may help patients reclaim confidence and facial harmony after medication-driven weight loss. Find out more in our press release galderma.com/news/galderma-… #AdvancingDermatology

Galderma will host an H1 2025 trading update call today at 1pm CET. We invite investors to attend to learn about our performance: investors.galderma.com/events-present…. A recording will also be made available after the event.